Please login to the form below

Not currently logged in
Email:
Password:

Indian court rejects Novartis patent demand

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

Novartis was demanding that India grant a patent for Glivec to prevent cheap copies being made. The government in New Delhi opposed the move, saying that granting such a patent would violate India's patent legislation.

Novartis has been seeking a patent for Glivec in India, challenging the Indian patent law which currently does not protect incremental innovation. Indian law does not grant patents for modifications to old medicines, but only to properly innovative drugs developed after 1995.

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics